Differential distribution of immune checkpoints across molecular subtypes of colorectal cancer

The recent introduction of immune checkpoint inhibitor therapy has significantly improved outcomes for patients with colorectal cancer (CRC). The most pronounced clinical benefits were observed in patients with immunogenic microsatellite instable (MSI)/deficient MMR (dMMR) tumors. However, emerging...

Full description

Bibliographic Details
Published in:OncoImmunology
Main Authors: Sofia Edin, Björn Gylling, Xingru Li, Åsa Stenberg, Anna Löfgren-Burström, Bethany van Guelpen, Agnes Ling, Ingrid Ljuslinder, Richard Palmqvist
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Subjects:
BRAF
colorectal cancer
immune checkpoints
immunotherapy
KRAS
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2546406

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2025.2546406

Similar Items